Not currently recruiting at UCSF
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Summary
- Eligibility
- for people ages 15-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Sofia G Verstraete
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Sofia G Verstraete
Assistant Professor, Pediatrics. Authored (or co-authored) 17 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- ID
- NCT03926130
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated